Brillpharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.88 M
as on 24-10-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.75 Cr
as on 24-10-2024
- Revenue 21.33%
(FY 2023)
- Profit 41.04%
(FY 2023)
- Ebitda 53.60%
(FY 2023)
- Net Worth -28.66%
(FY 2023)
- Total Assets 3.07%
(FY 2023)
About Brillpharma
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.88 M.
The company has closed loans amounting to ₹3.75 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ramachandran Nair, Priti Nair, and Thembalath Kutty serve as directors at the Company.
- CIN/LLPIN
U24233MH2012FTC229720
- Company No.
229720
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
16 Apr 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Brillpharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramachandran Nair  | Director | 16-Apr-2012 | Current |
| Priti Nair | Director | 16-Apr-2012 | Current |
| Thembalath Kutty | Director | 20-Mar-2015 | Current |
Financial Performance of Brillpharma.
Brillpharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 21.33% increase. The company also saw a substantial improvement in profitability, with a 41.04% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Brillpharma?
In 2023, Brillpharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Haysinth Investments And Traders Pvt LtdActive 35 years 3 months
Thembalath Kutty is a mutual person
Charges (Loans)
₹0
₹37.50 M
Charges Breakdown by Lending Institutions
- Others : 3.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2016 | Others | ₹3.75 Cr | Satisfied |
How Many Employees Work at Brillpharma?
Brillpharma has a workforce of 92 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Brillpharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Brillpharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
